Scientific Plenary

P1400 - Molecular Medicine—Can We Afford It?

Sunday, September 7
8:00-9:15 AM

1.0 CME/CE Credit

Rapid advancements in genomic technologies have led to a greater understanding of the underlying molecular basis for disease. This understanding and the incorporation of genome-based strategies for drug and diagnostic development have led to an increasing number of targeted therapeutics and treatment options for patients across a wide spectrum of disease. Practitioners can now use molecular information to diagnose or to determine which patient will benefit from an intervention. These opportunities for more precise treatment have led to a rise in the clinical demand for molecular testing across all medical specialties.

However, new technology comes with new costs—we want to use this technology to provide new information to physicians and patients, but who will pay for this service and what is its true value to patients and society? While molecular medicine has been successfully used to improve diagnosis and treatment, have we focused too much on isolated success stories to justify its wider use?

As our health system struggles to shift from paying for volume to paying for value, health economists seek to define and measure the cost, benefit, utility, and value of health care practices. How does genomic/molecular testing fit into traditional and new health economic models? Pathologists must consider the economic implications of the burgeoning use of molecular medicine on the health care system, as well as the individual laboratory and patient.

We invite you to join a stimulating conversation among three national thought leaders on this critical topic. Debra G.B. Leonard, MD, PhD, FCAP, a pathologist at the University of Vermont, is well versed in both the technical and business issues of molecular testing; and David O. Meltzer, MD, PhD, a health economist at the University of Chicago, will focus on measuring the economic impacts of genomic medicine. Adam C. Berger, PhD, director of the prestigious Institute of Medicine's Roundtable on Translating Genomic-Based Research for Health, will moderate the session. Don't miss this thought-provoking session!

You will learn to:

  • Discuss the value of using genomics and molecular techniques in diagnosis and treatment
  • Explain the economic issues and concerns that accompany the use of molecular medicine for patient care
  • Identify the uses and limitations of existing metrics of value as they are applied to molecular testing and genomic medicine

Cosponsored by Association for Molecular Pathology